M Holdings Securities Inc. Acquires New Shares in Sanofi $SNY

Posted by Stanley Muller on Aug 31st, 2026

M Holdings Securities Inc. acquired a new position in Sanofi (NASDAQ:SNY – Free Report) in the 2nd quarter, Holdings Channel reports. The firm acquired 20,863 shares of the company’s stock, valued at approximately $906,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Archer Investment Corp purchased a new stake in Sanofi in the second quarter valued at $174,000. Pinnacle West Asset Management Inc. acquired a new position in shares of Sanofi in the 2nd quarter valued at $271,000. Trust Co. of Vermont purchased a new position in shares of Sanofi during the 2nd quarter worth $212,000. Fiduciary Financial Group LLC grew its holdings in shares of Sanofi by 33.8% during the 2nd quarter. Fiduciary Financial Group LLC now owns 8,403 shares of the company’s stock worth $358,000 after purchasing an additional 2,124 shares during the period. Finally, Fulton Bank N.A. increased its position in shares of Sanofi by 5.6% during the 2nd quarter. Fulton Bank N.A. now owns 68,196 shares of the company’s stock worth $2,909,000 after purchasing an additional 3,623 shares during the last quarter. Institutional investors and hedge funds own 14.03% of the company’s stock.

Analysts Set New Price Targets

SNY has been the topic of several research analyst reports. Morgan Stanley set a $49.00 price objective on shares of Sanofi in a report on Wednesday, July 8th. Weiss Ratings lowered shares of Sanofi from a “hold (c-)” rating to a “sell (d)” rating in a research note on Monday, August 3rd. Finally, Wall Street Zen upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Saturday. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Sanofi currently has an average rating of “Hold” and a consensus target price of $49.50.

Get Our Latest Analysis on Sanofi

Sanofi Price Performance

NASDAQ:SNY opened at $44.82 on Monday. Sanofi has a 52 week low of $40.89 and a 52 week high of $52.68. The stock’s fifty day moving average is $43.67 and its two-hundred day moving average is $44.80. The stock has a market capitalization of $108.66 billion, a price-to-earnings ratio of 23.47, a price-to-earnings-growth ratio of 1.37 and a beta of 0.35. The company has a quick ratio of 0.64, a current ratio of 0.99 and a debt-to-equity ratio of 0.21.

Sanofi (NASDAQ:SNY – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The company reported $2.41 earnings per share for the quarter. The business had revenue of $13.36 billion during the quarter. Sanofi had a return on equity of 14.19% and a net margin of 8.66%.The company’s quarterly revenue was up 16.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.24 earnings per share. Research analysts anticipate that Sanofi will post 5.01 EPS for the current year.

About Sanofi

(Free Report)

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.